Rasagiline adjunct therapy in patients with Parkinson's disease: Posthoc analyses of the PRESTO and LARGO trials

Parkinsonism and Related Disorders

Volumn 19, Issue 11, 2013, Pages 930-936

  Elmer, Lawrence W ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Agonist; Bradykinesia; Entacapone; Fluctuation; Parkinson; Rasagiline

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; RASAGILINE;

ARTICLE; BRADYKINESIA; CLINICAL EFFECTIVENESS; CONFUSION; DIZZINESS; DYSKINESIA; HALLUCINATION; HUMAN; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RIGIDITY; SOMNOLENCE; TREMOR; VOMITING;

AGONIST; BRADYKINESIA; ENTACAPONE; FLUCTUATION; PARKINSON; RASAGILINE;

AGED; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84886589469     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.06.001     Document Type: Article

References (32)

1. Parkinson Study Group Acontrolled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002, 59:1937-1943.
2. Olanow C.W., Hauser R.A., Jankovic J., Langston W., Lang A., Poewe W., et al. Arandomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008, 23:2194-2201.
3. Parkinson Study Group Arandomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005, 62:241-248.
4. Rascol O., Brooks D.J., Melamed E., Oertel W., Poewe W., Stocchi F., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365:947-954.
5. Fox S.H., Katzenschlager R., Lim S.Y., Ravina B., Seppi K., Coelho M., et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011, 26:S2-S41.
6. Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronseth G., Bronte-Stewart H., et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2006, 66:983-995.
7. Once-daily rasagiline produces consistent treatment benefits in US and European studies of Parkinson's disease patients. (Abstract). Eur J Neurol 2006, 13:95. Schwid SR for The PRESTO and LARGO Investigators.
8. Poewe W for the PRESTO and LARGO Investigators. Rasagiline provides significant benefits as adjunct therapy in patients with moderate Parkinson's disease: subgroup analyses. In: 10th congress of the European federation of neurological societies 2006, September 2-5. p. 1193.
9. Elmer LW for the Parkinson Study Group. Rasagiline is effective and well tolerated in the treatment of Parkinson's disease (PD) patients with levodopa-related motor fluctuations receiving concomitant dopamine agonist (DA) therapy. In: The 130th annual meeting of the American neurological association, San Diego, CA, September 25-28, 2005. p. 258.
10. Rascol O, Brooks DJME, Oertel W, Poewe W, Stocchi F, Tolosa E, etal. Rasagiline is effective and well tolerated in the treatment of moderate to advanced Parkinson's disease (PD) patients receiving concomitant dopamine agonist therapy. In: 16th international congress on Parkinson's disease and related disorders Berlin, Germany, June 5-9, 2005. p. 18.
11. Elmer LW for the PRESTO and LARGO Investigators. Adjunctive rasagiline provides significant benefits in all cardinal symptoms in patients with moderate to advanced Parkinson's disease. In: Movement disorder society's 12th international congress of Parkinson's disease and movement disorders, June 22-26, 2008. p. 666.
12. Elmer LW for the Parkinson Study Group. Rasagiline is effective and well tolerated in Parkinson's disease (PD) patients with levodopa-related motor fluctuations receiving entacapone. In: Presented at the 10th congress of the European federation of neurological societies, September 2-5, 2006, Glasgow, Scotland, United Kingdom. p. 1167.
13. Joelson S., Joelson I.B., Wallander M.A. Geographical variation in adverse event reporting rates in clinical trials. Pharmacoepidemiol Drug Saf 1997, 6(Suppl.3):S31-S35.
14. Griffin J.P. Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries. Br J Clin Pharmacol 1986, 22(Suppl.1):83S-100S.
15. Olanow C.W., Watts R.L., Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001, 56:S1-S88.
16. Koller W.C., Tse W. Unmet medical needs in Parkinson's disease. Neurology 2004, 62:S1-S8.
17. Silver D.E., Buck P.O. Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review. Int.J Neurosci 2011, 121:485-489.
18. Fishman P.S. Paradoxical aspects of parkinsonian tremor. Mov Disord 2008, 23:168-173.
19. Hauser R.A., Gauger L., Anderson W.M., Zesiewicz T.A. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000, 15:658-663.
20. Weintraub D., Koester J., Potenza M.N., Siderowf A.D., Stacy M., Voon V., et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010, 67:589-595.
21. Weintraub D., Siderowf A.D., Potenza M.N., Goveas J., Morales K.H., Duda J.E., et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006, 63:969-973.
22. Mirapex (pramipexole dihydrochloride) prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc; Ridgefield, CT, Rev. 3/2013.
23. Perez-Lloret S., Rascol O. Safety of rasagiline for the treatment of Parkinson's disease. Expert Opin Drug Saf 2011, 10:633-643.
24. Elmer L., Schwid S., Eberly S., Goetz C., Fahn S., Kieburtz K., et al. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. JNeurol Sci 2006, 248:78-83.
25. Schwid S., Parkinson Study Group Safety of rasagiline in combination with serotonin reuptake inhibitors. Ann Neurol 2005, 58(Suppl.9):S56.
26. Tolosa E., Stern M.B. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease. Eur J Neurol 2012, 19:258-264.
27. Jenner J., Laar van T. Visual hallucinations in Parkinson's disease. International encyclopedia of rehabilitation 2013, Available from:, [accessed 05.02.13]. http://cirrie.buffalo.edu/encyclopedia/en/article/147/, J.H. Stone, M. Blouin (Eds.).
28. Azilect (rasagiline mesylate) prescribing information. Teva Pharmaceutical Industries, Inc; Kfar Saba, Israel. Revised 8/2012.
29. Wolters E.C. PD-related psychosis: pathophysiology and therapeutical strategies. JNeural Transm 2006, 71(Suppl.):31-37.
30. Reichmann H., Jost W.H. Efficacy and tolerability of rasagiline in daily clinical use-a post-marketing observational study in patients with Parkinson's disease. Eur J Neurol 2010, 17:1164-1171.
31. Tarrants M.L., Denarie M.F., Castelli-Haley J., Millard J., Zhang D. Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence. Am J Geriatr Pharmacother 2010, 8:374-383.
32. Shulman L.M., Gruber-Baldini A.L., Anderson K.E., Fishman P.S., Reich S.G., Weiner W.J. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol 2010, 67:64-70.